Gepotidacin is a triazaacenaphthylene bacterial type II topoisomerase inhibitor used experimentally. It has been in phase III of clinical trials since 2019 for the treatment of gonorrhea, however gepotidacin has demonstrated antibiotic activity against a variety of bacteria.
Machine-generated and unreviewed. Identity, structure and cross-references come straight from ChEBI's and CARD's own data; no curator has signed off on this record yet.
triazaacenaphthylene antibioticARO:3007164
ARO:3007164| Molecular formula | C24H28N6O3 |
|---|---|
| Charge | 0 |
| Average mass | 448.5 Da |
| Monoisotopic mass | 448.22228878 Da |
| Source | PubChem · retrieved 2026-08-29 |
| InChIKey | PZFAZQUREQIODZ-LJQANCHMSA-N |
C1CC2=CC(=NC=C2OC1)CNC3CCN(CC3)C[C@@H]4CN5C(=O)C=CC6=C5N4C(=O)C=N6
InChI=1S/C24H28N6O3/c31-22-4-3-20-24-29(22)15-19(30(24)23(32)13-27-20)14-28-7-5-17(6-8-28)25-11-18-10-16-2-1-9-33-21(16)12-26-18/h3-4,10,12-13,17,19,25H,1-2,5-9,11,14-15H2/t19-/m1/s1
| Source | Native ID | Label | Minted CURIE | Version |
|---|---|---|---|---|
| ARO | ARO:3007092 |
gepotidacin | antibioticmech:aro-b2e68d25c8 |
2026-08-30 |
Seeded from data/raw/ inventories (ARO)
Re-seeded from updated data/raw/ inventories
Re-seeded from updated data/raw/ inventories